• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 17, 2022 at 11:32: PM
via Zosano Pharma's migraines are getting worse: The biotech is looking at strategic alternatives and laying off 31% of its staff. The news follows last month's FDA decision to decline to review the company's already-rejected drug.

article source
 

<



Similar threads

cafead
Bankrupt Zosano sells intradermal delivery tech to Emergex Vaccines
Replies
0
Views
91
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Emergex looks to microneedle patches with Zosano Pharma acquisition
Replies
0
Views
88
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Zosano goes bankrupt after FDA rejects migraine drug delivery patch
Replies
0
Views
170
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
After filing for bankruptcy, rejected migraine drug developer Zosano’s value more than halved
Replies
0
Views
116
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
No go for Zosano as FDA knockback triggers suspension of transdermal migraine patch program
Replies
0
Views
111
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote